Replimune shares rebound after FDA setback on melanoma drug application. Analyst downgrades point to uncertainty and financial challenges ahead.
https://www.gurufocus.com/news/2998252/replimune-repl-shares-rebound-despite-fda-setback
Replimune shares rebound after FDA setback on melanoma drug application. Analyst downgrades point to uncertainty and financial challenges ahead.
https://www.gurufocus.com/news/2998252/replimune-repl-shares-rebound-despite-fda-setback
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.